Impaired fasting glucose appears to be a stronger risk factor for type 2 diabetes mellitus (T2DM) than metabolic syndrome (MetS), reports a new Japan study. The coexistence of the two factors confers the highest T2DM risk.
A robust association exists between improvements in carbohydrate quality index (CQI) and concurrent favourable cardiovascular disease (CVD) risk factor changes maintained over time in overweight/obese adults with metabolic syndrome (MetS), according to a study.
A new noninvasive risk score―incorporating factors such as waist circumference, age, sex, and histories of hyperglycaemia and diabetes in the family― reliably identifies those at high dysglycaemia risk, reports a new Saudi Arabia study.
Sleep disorder in nonstandard shift workers appears to contribute to more severe hypogonadal symptoms and lower testosterone levels when compared with daytime workers and nonstandard shift workers without sleep disorder, according to a study.
A US-based retrospective cohort study has shown no difference in the rates of mortality and cardiovascular disease (CVD) with initiation and continuous use of either analogue or human insulin in insulin-naïve adults with type 2 diabetes (T2D).
The risk of incident vertebral fractures (VFs) is lower among acromegaly patients with biochemically active disease treated with pasireotide LAR (Pasi) compared with those on pegvisomant (PegV), reports a recent study, which also confirms that the presence of pre-existent VFs is the main cause of incident VFs.
The inclusion of two proanthocyanidin (PA)-rich apples into normal diets improves cardiovascular disease (CVD) risk factors by reducing total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and intercellular cell adhesion molecule-1 (ICAM-1), as well as increasing microvascular vasodilation, in individuals with mildly elevated serum cholesterol concentrations, a recent study has shown.
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
Use of the feminizing hormone therapy medroxyprogesterone acetate (MPA) results in minimal side effects, unchanged oestradiol levels and a decline in testosterone in a cohort of transwomen, a study has found.